ストックスクリーナーアプリを入手
121.88
0.70%
-0.86
前日終値:
$122.74
開ける：
$122.49
24時間の取引高:
1.50M
Relative Volume:
0.22
時価総額：
$151.19B
収益：
$29.05B
当期純損益:
$8.11B
株価収益率:
18.88
EPS:
6.4563
ネットキャッシュフロー:
$9.16B
1週間 パフォーマンス:
-2.26%
1か月 パフォーマンス:
-1.63%
6か月 パフォーマンス:
+9.30%
1年 パフォーマンス:
+32.66%
1日の値動き範囲:
$121.19
$122.59
1週間の範囲:
$121.19
$125.27
52週間の値動き範囲:
$88.57
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
GILD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
121.86 | 152.28B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,069.08 | 961.86B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.60 | 498.60B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.56 | 403.83B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
137.86 | 264.54B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
105.78 | 261.26B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Miracle Mile Advisors LLC Buys 25,117 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
CapWealth Advisors LLC Has $27.04 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Bank Pictet & Cie Europe AG Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Q3 EPS Forecast Raised by Zacks Research - MarketBeat
Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026 - Finviz
What's Driving the Market Sentiment Around Gilead Sciences Inc? - Benzinga
Los Angeles Capital Management LLC Purchases 1,223,895 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Lee Johnson Capital Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Ascent Group LLC Buys 11,926 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today - sharewise.com
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead (GILD) reaches pricing agreement with US government to lower drug costs - MSN
Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs - Insider Monkey
Daniel Patrick O'day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Abacus FCF Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Is Gilead Sciences (GILD) An Affordable Healthcare Stocks to Invest In? - Insider Monkey
Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit - ts2.tech
After 25 Years, Recurrent Genital Herpes Treatment Gains Corporate Partner - Vax-Before-Travel
November phase III successes led by HIV wins from Gilead, Merck - BioWorld MedTech
Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact - Investing.com
Repare Therapeutics Signs Asset Purchase Agreement With Gilead Sciences - TradingView — Track All Markets
Liver Fibrosis Treatment Market Is Booming So Rapidly | Gilead Sciences, Inc., Merck & Co., Inc. - openPR.com
Sapient Capital LLC Sells 8,077 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by E. Ohman J or Asset Management AB - MarketBeat
Gilead Sciences exercises option to license Assembly Biosciences Helicase-Primase Inhibitor programs for... - Medical Dialogues
Meyer Handelman Co. Has $38.56 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Highland Capital Management LLC Invests $1.76 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc.'s (NASDAQ:GILD) Prospects Need A Boost To Lift Shares - 富途牛牛
Pacer Advisors Inc. Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to acquire Repare’s RP-3467 - Pharmaceutical Technology
Norden Group LLC Has $3.40 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Stocktwits
December 2028 Options Now Available For Gilead Sciences (GILD) - Nasdaq
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise - marketscreener.com
Vontobel Holding Ltd. Acquires 394,567 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug By Investing.com - Investing.com South Africa
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug - Investing.com Canada
Swedbank AB Acquires 58,405 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million - Benzinga
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Investing News Network
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset - GuruFocus
Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million By Investing.com - Investing.com Canada
Gilead to buy Repare Thera’s cancer candidate for up to $30M - MSN
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million - Investing.com
Repare Therapeutics Announces Acquisition Of Pol? ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration - marketscreener.com
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Bluefield Daily Telegraph
Global X Japan Co. Ltd. Acquires 11,034 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025 - ts2.tech
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
1.02%
0.04%
大文字化:
|
ボリューム (24 時間):